AAV Vector Modification and Screening

Through rational design and in vitro/in vivo screening platform, we have developed novel rAAV capsid variants of various serotypes with strong tissue targeting, high induction efficiency, and low immunogenicity.
We have also optimized recombinant baculovirus virus design to produce high quality AAV vectors in Sf9 cells.

Gene Expression Cassette Optimization

Through optimizing rAAV vector and GOI sequences, we have improved target protein expression level, enhanced tissue specificity of gene expression while reducing immunogenicity.

Based on the Sf9 insect cell expression system, we have established rAAV GMP production platform with large-scale capacity, high yields and low costs.

With an optimized purification process, we have controlled empty capsid levels less than 5%, significantly enhancing product safety, setting a strong competitive advantage.

Established a full-spectrum AAV quality control and assurance system that meets the regulatory standards across the United States, European Union, and China for gene therapy products.